For adults and children with hemophilia A
The safety of AFSTYLA was shown in 258 previously treated children, adolescents, and adults over 19,545 exposure days.
Zero inhibitors in clinical trials with previously treated people.
*AsBR=annualized spontaneous bleeding rate.
Sign up today.
Use these tools to help you decide.
CSL Behring makes it easy to start on AFSTYLA. You’ll also have access to comprehensive support services that can make a meaningful difference in the lives of people with bleeding disorders.
Call 1-800-676-4266 to get detailed information about the services available to you.
After more than 30 YEARS of experience in bleeding disorders, CSL Behring remains committed to developing innovative therapies for the people who need them